Relation of Salivary MMP-8 with Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma: a Cross Sectional Analytical Study

Overview

Journal BMJ Open

Specialty General Medicine

Date 2022 Dec 16

PMID 36523229

Authors

Anum Kazmi

Zia Abbas

Zohra Saleem

Safdar Haider

Waqas Ahmed Farooqui

Shaheen Ahmed

Affiliations

Soon will be listed here.

Abstract

Objectives: We aim to evaluate salivary matrix metalloproteinases (MMP-8) levels in oral submucous fibrosis (OSF) and oral squamous cell carcinoma (OSCC) for the purpose of diagnosis at the early stage via non-invasive method.

Setting: The study was multicentre, carried out at a tertiary care hospital in Karachi, Pakistan.

Participants: A total 60 participants of any age, sex and ethnicity were randomly selected for the purpose of this study. Patients demonstrating clinical evidence of OSF and biopsy-proven cases of OSCC were included. Patients with indeterminate histopathological report, immunodeficiency, autoimmune disorder, chronic medical and periodontal disease (periodontal depth greater than 5 mm) and individuals with interincisal mouth opening greater than 35 mm were excluded from the study.

Interventions: Salivary MMP-8 levels were observed in OSF, healthy and OSCC groups by using ELISA. One way analysis of variance was applied to establish whether MMP-8 levels of disease-free individuals and patients suffering from OSF and OSCC differed from each other.

Results: Statistically significant difference in salivary MMP-8 expression in diseased and control group was observed. MMP-8 levels in OSCC (0.64 ng/mL) and OSF (0.66 ng/mL) were underexpressed as compared with healthy participants (7.9 ng/mL).

Conclusion: MMP-8 levels were underexpressed in OSCC and OSF patients as compared with controls, which imply that MMP-8 level has an inverse relation with OSCC and OSF.

Citing Articles

Association of salivary mmp-8 gene polymorphism with its protein expression in oral submucous fibrosis patients.

Qamar R, Khatoon A, Mirza T, Razi A, Khurshid Y Odontology. 2025; .

PMID: 39994129 DOI: 10.1007/s10266-025-01074-9.

References

Hung Y, Tsai C, Wu C, Shih L, Chen Y, Liu Y . The Contribution of Matrix Metalloproteinase-8 Promoter Polymorphism to Oral Cancer Susceptibility. In Vivo. 2017; 31(4):585-590. PMC: 5566907. DOI: 10.21873/invivo.11098. View

Kapoor C, Vaidya S, Wadhwan V, Kaur G, Pathak A . Seesaw of matrix metalloproteinases (MMPs). J Cancer Res Ther. 2016; 12(1):28-35. DOI: 10.4103/0973-1482.157337. View

Cox J, Starr A, Kappelhoff R, Yan R, Roberts C, Overall C . Matrix metalloproteinase 8 deficiency in mice exacerbates inflammatory arthritis through delayed neutrophil apoptosis and reduced caspase 11 expression. Arthritis Rheum. 2010; 62(12):3645-55. DOI: 10.1002/art.27757. View

Ross J, Kaur P, Sheehan C, Fisher H, Kaufman Jr R, Kallakury B . Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol. 2003; 16(3):198-205. DOI: 10.1097/01.MP.0000056984.62360.6C. View

Pradhan-Palikhe P, Vesterinen T, Tarkkanen J, Leivo I, Sorsa T, Salo T . Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer. Oral Oncol. 2010; 46(7):514-8. DOI: 10.1016/j.oraloncology.2010.03.002. View

Magary S, Ryan M, Tarnuzzer R, Kornberg L . Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in laryngeal and pharyngeal squamous cell carcinoma: A quantitative analysis. Otolaryngol Head Neck Surg. 2000; 122(5):712-6. DOI: 10.1016/S0194-5998(00)70202-6. View

Panneerselvam K, Ishikawa S, Krishnan R, Sugimoto M . Salivary Metabolomics for Oral Cancer Detection: A Narrative Review. Metabolites. 2022; 12(5). PMC: 9144467. DOI: 10.3390/metabo12050436. View

Nurmenniemi S, Koivula M, Nyberg P, Tervahartiala T, Sorsa T, Mattila P . Type I and III collagen degradation products in serum predict patient survival in head and neck squamous cell carcinoma. Oral Oncol. 2011; 48(2):136-40. DOI: 10.1016/j.oraloncology.2011.09.002. View

Agarwal D, Goodison S, Nicholson B, Tarin D, Urquidi V . Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation. 2003; 71(2):114-25. DOI: 10.1046/j.1432-0436.2003.710202.x. View

10.

Ponti G, Manfredini M, Tomasi A . Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Crit Rev Oncol Hematol. 2019; 141:36-42. DOI: 10.1016/j.critrevonc.2019.06.005. View

11.

Kim J, Jeong Y, Lee E, Park J, Seo H, Kim H . Suppression of neuroinflammation by matrix metalloproteinase-8 inhibitor in aged normal and LRRK2 G2019S Parkinson's disease model mice challenged with lipopolysaccharide. Biochem Biophys Res Commun. 2017; 493(2):879-886. DOI: 10.1016/j.bbrc.2017.09.129. View

12.

Miguel A, Mello F, Melo G, Rivero E . Association between immunohistochemical expression of matrix metalloproteinases and metastasis in oral squamous cell carcinoma: Systematic review and meta-analysis. Head Neck. 2019; 42(3):569-584. DOI: 10.1002/hed.26009. View

13.

Balbin M, Fueyo A, Tester A, Pendas A, Pitiot A, Astudillo A . Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet. 2003; 35(3):252-7. DOI: 10.1038/ng1249. View

14.

Arora K, Nayyar A, Kaur P, Arora K, Goel A, Singh S . Evaluation of Collagen in Leukoplakia, Oral Submucous Fibrosis and Oral Squamous Cell Carcinomas Using Polarizing Microscopy and Immunohistochemistry. Asian Pac J Cancer Prev. 2018; 19(4):1075-1080. PMC: 6031770. DOI: 10.22034/APJCP.2018.19.4.1075. View

15.

Astrom P, Juurikka K, Hadler-Olsen E, Svineng G, Cervigne N, Coletta R . The interplay of matrix metalloproteinase-8, transforming growth factor-β1 and vascular endothelial growth factor-C cooperatively contributes to the aggressiveness of oral tongue squamous cell carcinoma. Br J Cancer. 2017; 117(7):1007-1016. PMC: 5625665. DOI: 10.1038/bjc.2017.249. View

16.

Ahmed Haji Omar A, Haglund C, Virolainen S, Hayry V, Atula T, Kontio R . MMP-7, MMP-8, and MMP-9 in oral and cutaneous squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 119(4):459-67. DOI: 10.1016/j.oooo.2014.12.019. View

17.

Kuropkat C, Plehn S, Herz U, Dunne A, Renz H, Werner J . Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer. Anticancer Res. 2002; 22(4):2221-7. View

18.

Nagase H, Visse R, Murphy G . Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69(3):562-73. DOI: 10.1016/j.cardiores.2005.12.002. View

19.

Ren Z, Wu K, Yang R, Liu Z, Cao W . Differential expression of matrix metalloproteinases and miRNAs in the metastasis of oral squamous cell carcinoma. BMC Oral Health. 2020; 20(1):24. PMC: 6988311. DOI: 10.1186/s12903-020-1013-0. View

20.

Chang Y, Yang S, Tai K, Chou M, Hsieh Y . Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncol. 2002; 38(2):195-200. DOI: 10.1016/s1368-8375(01)00045-8. View